Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bremelanotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R known ✓ | P32245 | 20/20 | 0.71 |
| ▸ | MC3R | P41968 | 8/20 | 0.71 |
| ▸ | MC1R | Q01726 | 5/20 | 0.71 |
| ▸ | MC5R | P33032 | 5/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bremelanotide SCHEMBL20356841 | 1.00 | MC4R (0.71) | MC4RMC3RMC1RMC5R | |
| Bremelanotide SCHEMBL20356840 | 1.00 | MC4R (0.71) | MC4RMC3RMC1RMC5R | |
| Bremelanotide SCHEMBL14498253 | 1.00 | MC4R (0.71) | MC4RMC3RMC1RMC5R | |
| Bremelanotide SCHEMBL29405727 | 1.00 | MC4R (0.71) | MC4RMC3RMC1RMC5R | |
| Bremelanotide SCHEMBL29575881 | 0.99 | MC4R (0.70) | MC4RMC3RMC1RMC5R | |
| SCHEMBL13064154 | 0.98 | MC4R (0.67) | MC4RMC3RMC1RMC5R | |
| Melatonan SCHEMBL29473785 | 0.97 | MC4R (0.67) | MC4RMC3RMC1RMC5R | |
| SCHEMBL13064117 | 0.96 | MC4R (0.66) | MC4RMC3RMC1RMC5R | |
| SCHEMBL10307917 | 0.95 | MC4R (0.66) | MC4RMC3RMC1RMC5R | |
| SCHEMBL19473791 | 0.95 | MC4R (0.66) | MC4RMC3RMC1RMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11590209-B2 | Use of bremelanotide in patients with controlled hypertension | PALATIN TECHNOLOGIES, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210220444-A1 | USE OF BREMELANOTIDE IN PATIENTS WITH CONTROLLED HYPERTENSION | UBS AG, STAMFORD BRANCH, AS ADMINISTRATIVE AGENT | 2021-07-22 | — | — | US | disclosed |
| US-20210060120-A1 | USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION | PALATIN TECHNOLOGIES, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20190216888-A1 | USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION | PALATIN TECHNOLOGIES, INC. | 2019-07-18 | — | — | US | disclosed |
| US-10286034-B2 | Uses of bremelanotide in therapy for female sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180085425-A1 | Uses of Bremelanotide in Therapy for Female Sexual Dysfunction | PALATIN TECHNOLOGIES, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9700592-B2 | Uses of bremelanotide in therapy for female sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-9352013-B2 | Uses of bremelanotide in therapy for female sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150231196-A1 | Uses of Bremelanotide in Therapy for Female Sexual Dysfunction | PALATIN TECHNOLOGIES, INC. | 2015-08-20 | — | — | US | disclosed |
| US-20140378392-A1 | Uses Of Bremelanotide in Therapy for Female Sexual Dysfunction | PALATIN TECHNOLOGIES, INC. | 2014-12-25 | — | — | US | disclosed |
| WO-2009151714-A2 | THERAPEUTIC FOR TREATMENT OF CIRCULATORY SHOCK, ISCHEMIA, INFLAMMATORY DISEASE AND RELATED CONDITIONS | PALATIN TECHNOLOGIES, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009120656-A1 | PHARMACEUTICAL FOR OCULAR INDICATIONS | PALATIN TECHNOLOGIES, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150231196-A1 | Uses of Bremelanotide in Therapy for Female Sexual Dysfunction | GNRHR, GLP1R, SCTR | MC4R 29/4885MC3R 31/4885MC1R 23/4885 |
| US-10286034-B2 | Uses of bremelanotide in therapy for female sexual dysfunction | GNRHR, GLP1R, SCTR | MC4R 30/4885MC3R 32/4885MC1R 23/4885 |
| US-20190216888-A1 | USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION | GNRHR, GLP1R, SCTR | MC4R 30/4885MC3R 32/4885MC1R 23/4885 |
| US-11590209-B2 | Use of bremelanotide in patients with controlled hypertension | CRH, GNRHR, GLP1R | MC4R 44/4885MC3R 39/4885MC1R 41/4885 |
| US-20210220444-A1 | USE OF BREMELANOTIDE IN PATIENTS WITH CONTROLLED HYPERTENSION | CRH, GNRHR, GLP1R | MC4R 44/4885MC3R 39/4885MC1R 41/4885 |
| US-20180085425-A1 | Uses of Bremelanotide in Therapy for Female Sexual Dysfunction | GNRHR, GLP1R, SCTR | MC4R 30/4885MC3R 32/4885MC1R 23/4885 |
| US-20210060120-A1 | USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION | GNRHR, GLP1R, SCTR | MC4R 30/4885MC3R 32/4885MC1R 23/4885 |
| US-20140378392-A1 | Uses Of Bremelanotide in Therapy for Female Sexual Dysfunction | GNRHR, GLP1R, SCTR | MC4R 29/4885MC3R 31/4885MC1R 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.